Pascal Roy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9018213/publications.pdf

Version: 2024-02-01

147801 69250 6,228 100 31 77 citations h-index g-index papers 108 108 108 8050 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of dataset size and interactions on the prediction performance of logistic regression and deep learning models. Computer Methods and Programs in Biomedicine, 2022, 213, 106504.	4.7	39
2	Coffee consumption and seizure frequency in patients with drug-resistant focal epilepsy. Epilepsy and Behavior, 2022, 126, 108486.	1.7	7
3	Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC). Cancers, 2022, 14, 2591.	3.7	2
4	Human Papilloma Virus Vaccination in Patients with Rheumatic Diseases in France: A Study of Vaccination Coverage and Drivers of Vaccination. Journal of Clinical Medicine, 2022, 11, 4137.	2.4	2
5	Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke. European Journal of Neurology, 2021, 28, 532-539.	3.3	4
6	Correcting the bias of the net benefit estimator due to rightâ€eensored observations. Biometrical Journal, 2021, 63, 893-906.	1.0	3
7	24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke. European Stroke Journal, 2021, 6, 168-175.	5.5	2
8	Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures. Vaccines, 2021, 9, 1462.	4.4	8
9	Clinical Characteristics and Outcome of Patients with Lacunar Infarcts and Concurrent Embolic Ischemic Lesions. Clinical Neuroradiology, 2020, 30, 511-516.	1.9	3
10	Comparison of crossover and parallelâ€group designs for the identification of a binary predictive biomarker of the treatment effect. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 59-64.	2.5	2
11	20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas. Melanoma Research, 2020, 30, 272-278.	1.2	4
12	Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial. Neurological Research and Practice, 2020, 2, 40.	2.0	7
13	Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis. Acta Neuropathologica Communications, 2020, 8, 190.	5.2	20
14	Cytomegalovirus infection in the first year after pediatric kidney transplantation. Nephrologie Et Therapeutique, 2019, 15, 44-50.	0.5	4
15	Individualized quantification of the benefit from reperfusion therapy using stroke predictive models. European Journal of Neuroscience, 2019, 50, 3251-3260.	2.6	О
16	Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial. Frontiers in Neurology, 2019, 10, 983.	2.4	3
17	Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. European Respiratory Journal, 2019, 54, 1900430.	6.7	43
18	Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial. JAMA Neurology, 2019, 76, 641.	9.0	63

#	Article	IF	CITATIONS
19	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. Journal of the National Cancer Institute, 2019, 111, 1186-1191.	6.3	13
20	Optimism Bias Correction in Omics Studies with Big Data: Assessment of Penalized Methods on Simulated Data. OMICS A Journal of Integrative Biology, 2019, 23, 207-213.	2.0	4
21	Energy Expenditure in Older People Hospitalized for an Acute Episode. Nutrients, 2019, 11, 2946.	4.1	5
22	Variance component analysis to assess protein quantification in biomarker discovery. Application to MALDIâ€TOF mass spectrometry. Biometrical Journal, 2018, 60, 262-274.	1.0	1
23	Whole exome sequencing in three families segregating a pediatric case of sarcoidosis. BMC Medical Genomics, 2018, 11, 23.	1.5	26
24	Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial. Breast Cancer Research and Treatment, 2018, 170, 303-312.	2.5	5
25	Clinical characteristics of unknown symptom onset stroke patients with and without diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch. International Journal of Stroke, 2018, 13, 66-73.	5.9	5
26	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 2018, 27, 1230-1239.	1.5	43
27	MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. New England Journal of Medicine, 2018, 379, 611-622.	27.0	912
28	Stroke With Unknown Time of Symptom Onset. Stroke, 2017, 48, 770-773.	2.0	51
29	Statistical method to compare massive parallel sequencing pipelines. BMC Bioinformatics, 2017, 18, 139.	2.6	4
30	Effect of informed consent on patient characteristics in a stroke thrombolysis trial. Neurology, 2017, 89, 1400-1407.	1.1	17
31	Predicting thyroid nodule malignancy at several prevalence values with a combined Bethesda-molecular test. Translational Research, 2017, 188, 58-66.e1.	5.0	4
32	Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3368-3374.	3.6	112
33	Bayesian inference for biomarker discovery in proteomics: an analytic solution. Eurasip Journal on Bioinformatics and Systems Biology, 2017, 2017, 9.	1.4	5
34	Growth curves for congenital adrenal hyperplasia from a national retrospective cohort. Journal of Pediatric Endocrinology and Metabolism, 2016, 29, 1379-1388.	0.9	16
35	Efficacy of naloxone in reducing postictal central respiratory dysfunction in patients with epilepsy: study protocol for a double-blind, randomized, placebo-controlled trial. Trials, 2016, 17, 529.	1.6	7
36	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. JAMA Oncology, 2016, 2, 901.	7.1	47

#	Article	IF	Citations
37	Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort. Orphanet Journal of Rare Diseases, 2016, 11, 165.	2.7	27
38	Partial validation of a French version of the ADHD-rating scale IV on a French population of children with ADHD and epilepsy. Factorial structure, reliability, and responsiveness. Epilepsy and Behavior, 2016, 58, 1-6.	1.7	18
39	Kendrick's extrication device and unstable pelvic fractures: Should a trochanteric belt be added? A cadaveric study. Injury, 2016, 47, 711-716.	1.7	1
40	Quantification of Treatment Effect Modification on Both an Additive and Multiplicative Scale. PLoS ONE, 2016, 11, e0153010.	2.5	12
41	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	1.8	22
42	Comparison of two next-generation sequencing kits for diagnosis of epileptic disorders with a user-friendly tool for displaying gene coverage, DeCovA. Applied & Translational Genomics, 2015, 7, 19-25.	2.1	19
43	Evaluation of Early Reperfusion Criteria in Acute Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 952-958.	2.0	2
44	Severity of postâ€partum hemorrhage after vaginal delivery is not predictable from clinical variables available at the time postâ€partum hemorrhage is diagnosed. Journal of Obstetrics and Gynaecology Research, 2015, 41, 199-206.	1.3	18
45	Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. British Journal of Cancer, 2015, 112, 971-976.	6.4	26
46	Variable selection for noisy data applied in proteomics. , 2014, , .		1
47	On a measure of information gain for regression models in survival analysis. Journal of Applied Statistics, 2014, 41, 2696-2708.	1.3	2
48	Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European crossâ€over controlled trial in a rare disease. Journal of Thrombosis and Haemostasis, 2014, 12, 1494-1502.	3.8	94
49	Pelvic-Floor Muscle Rehabilitation in Erectile Dysfunction and Premature Ejaculation. Physical Therapy, 2014, 94, 1731-1743.	2.4	27
50	Number needed to treat from absolute risk and incidence rate: How to make apples and oranges comparable?. Journal of Clinical Epidemiology, 2014, 67, 236-238.	5.0	6
51	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Test Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-up Stroke (WAKE-UP). International Journal of Stroke, 2014, 9, 829-836.	5.9	130
52	Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. Journal of Hepatology, 2014, 61, 891-902.	3.7	116
53	Specific vs general cognitive remediation for executive functioning in schizophrenia: A multicenter randomized trial. Schizophrenia Research, 2013, 147, 68-74.	2.0	72
54	Expected impact of a public health intervention in the presence of synergistic risk factors. Journal of Clinical Epidemiology, 2013, 66, 445-452.	5.0	0

#	Article	IF	CITATIONS
55	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8Âyears post-operative follow-up. Acta Neuropathologica, 2013, 126, 123-135.	7.7	395
56	Is Thyroid Cancer Recurrence Risk Increased After Transplantation?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3981-3988.	3.6	10
57	Validation of tumorâ€associated macrophage ferritin light chain as a prognostic biomarker in nodeâ€negative breast cancer tumors: A multicentric 2004 national PHRC study. International Journal of Cancer, 2012, 131, 426-437.	5.1	64
58	Quantitative and functional analyses of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. British Journal of Haematology, 2011, 153, 139-143.	2.5	17
59	Protein mass spectra data analysis for clinical biomarker discovery: a global review. Briefings in Bioinformatics, 2011, 12, 176-186.	6.5	23
60	A dietary supplement to improve the quality of sleep: a randomized placebo controlled trial. BMC Complementary and Alternative Medicine, 2010, 10, 29.	3.7	29
61	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1708-1716.	3.6	144
62	Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Annals of Oncology, 2009, 20, 1387-1396.	1.2	82
63	Mixed-model of ANOVA for measurement reproducibility in proteomics. Journal of Proteomics, 2009, 72, 974-981.	2.4	15
64	Inter-observer agreement in the identification of the two bundles of the anterior cruciate ligament using magnetic resonance imaging. Surgical and Radiologic Anatomy, 2008, 30, 557-562.	1.2	7
65	Comparative optimism in models involving both classical clinical and gene expression information. BMC Bioinformatics, 2008, 9, 434.	2.6	10
66	Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator. Clinical Breast Cancer, 2008, 8, 168-177.	2.4	20
67	Tumor necrosis factor-alpha -308 polymorphism in infertile men with altered sperm production or motility. Human Reproduction, 2008, 23, 2858-2866.	0.9	31
68	Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 545-552.	1.3	64
69	Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer, 2007, 109, 256-264.	4.1	17
70	Importance of data structure in comparing two dimension reduction methods for classification of microarray gene expression data. BMC Bioinformatics, 2007, 8, 90.	2.6	11
71	Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer. European Journal of Cancer Prevention, 2006, 15, 347-352.	1.3	4
72	Extensive multiallelic analysis of the relationship between HLA-DRB1 and rheumatoid arthritis using a Bayesian partition model. Genes and Immunity, 2006, 7, 487-493.	4.1	2

#	Article	IF	Citations
73	Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1471-1478.	0.8	65
74	Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. Annals of the Rheumatic Diseases, 2006, 66, 195-201.	0.9	24
75	Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection. Annals of Thoracic Surgery, 2005, 80, 423-427.	1.3	53
76	Contrast enhancement in atherosclerosis development in a mouse model: in vivo results at 2 Tesla. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2004, 17, 188-195.	2.0	28
77	Value of Rectal Ultrasound in Predicting Staging and Outcome in Patients With Rectal Adenocarcinoma. Diseases of the Colon and Rectum, 2004, 47, 1323-1330.	1.3	14
78	Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). American Journal of Ophthalmology, 2004, 137, 893-900.	3.3	86
79	Survival after proton-beam irradiation of uveal melanomas. American Journal of Ophthalmology, 2004, 137, 1002-1010.	3.3	56
80	Follicular Lymphoma International Prognostic Index. Blood, 2004, 104, 1258-1265.	1.4	1,552
81	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. Journal of Clinical Oncology, 2003, 21, 20-27.	1.6	420
82	What Is the Relevance of Obtaining Multiple Blood Samples for Culture? A Comprehensive Model to Optimize the Strategy for Diagnosing Bacteremia. Clinical Infectious Diseases, 2002, 35, 842-850.	5.8	82
83	Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976–1995. European Journal of Cancer Prevention, 2002, 11, 529-534.	1.3	24
84	Correlation of the WHO Schema for the Classification of Thymic Epithelial Neoplasms With Prognosis. American Journal of Surgical Pathology, 2002, 26, 1605-1611.	3.7	159
85	Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2002, 30, 769-775.	2.4	45
86	Reflexions from the experience of the French CLEOPATRE program and concerns about the status of clinical research on small cell lung cancer. Lung Cancer, 2001, 33, 303-307.	2.0	0
87	Qu'attend le cancérologue de l'échoendoscopie adans le cancer du rectum. Quelques réflexions. A Endoscopica, 2001, 31, 21-25.	cta 0.0	0
88	Methodological questions in sentinel lymph node analysis in breast cancer patients. Annals of Oncology, 2000, 11, 1381-1385.	1.2	3
89	Long-term survival in Hodgkin's disease patients. European Journal of Cancer, 2000, 36, 384-389.	2.8	56
90	Tagging sentinel lymph nodes: a study of 100 patients with breast cancer. European Journal of Cancer, 1999, 35, 569-573.	2.8	33

#	Article	IF	Citations
91	Using relative risk models for estimating synergy between two risk factors. , 1998, 17, 1357-1373.		11
92	Screening for neuroblastoma in children: elements for a statistical evaluation. Medical and Pediatric Oncology, 1998, 31, 401-407.	1.0	7
93	Prognostic comparison of the pathological classifications of gastric cancer: a population-based study. Histopathology, 1998, 33, 304-310.	2.9	26
94	Outcome of treatment of upper third vaginal recurrences of cervical and endometrial carcinomas with interstitial brachytherapy. International Journal of Radiation Oncology Biology Physics, 1998, 40, 421-426.	0.8	53
95	Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome. Blood, 1998, 91, 3574-3581.	1.4	263
96	Populationâ€based study of the treatment and prognosis of carcinoma of the rectum. British Journal of Surgery, 1997, 84, 1546-1550.	0.3	21
97	Population-based study of the treatment and prognosis of carcinoma of the rectum. British Journal of Surgery, 1997, 84, 1546-1550.	0.3	14
98	Combined curative radiation therapy alone in (T1) T2-3 rectal adenocarcinoma: a pilot study of 29 patients. Radiotherapy and Oncology, 1996, 38, 131-137.	0.6	19
99	Is neuroblastoma screening evaluation needed and feasible?. British Journal of Cancer, 1995, 71, 1125-1131.	6.4	45
100	Emergency balloon angioplasty and digital subtraction angiography in the management of an acute latrogenic occlusive dissection of a saphenous vein graft. Catheterization and Cardiovascular Diagnosis, 1989, 16, 176-179.	0.3	7